Atria Investments LLC Biomarin Pharmaceutical Inc Transaction History

Atria Investments LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $334,860 - $414,897	4,499 New	4,499 $370,000
Q3 2020 Nov 05, 2020	SELL	$71.87 - $131.03 $685,999 - $1.25 Million	-9,545 Closed	0 $0
Q2 2020 Sep 22, 2020	BUY	$79.55 - $124.22 $50,036 - $78,134	629 Added 7.05%	9,545 $1.18 Million
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $234,521 - $318,249	3,286 Added 58.37%	8,916 $753,000
Q4 2019 Feb 11, 2020	BUY	$64.27 - $86.37 $168,001 - $225,771	2,614 Added 86.67%	5,630 $476,000
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $24,196 - $30,554	-359 Reduced 10.64%	3,016 $203,000
Q2 2019 Aug 26, 2019	BUY	$80.35 - $93.9 $271,181 - $316,912	3,375 New	3,375 $243,000
Q2 2019 Aug 09, 2019	SELL	$80.35 - $93.9 $218,150 - $254,938	-2,715 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $20,713 - $24,260	-246 Reduced 8.31%	2,715 $241,000
Q4 2018 Feb 12, 2019	SELL	$80.14 - $106.07 $23,801 - $31,502	-297 Reduced 9.12%	2,961 $252,000
Q3 2018 Oct 09, 2018	BUY	$93.92 - $105.72 $29,772 - $33,513	317 Added 10.78%	3,258 $316,000
Q2 2018 Jul 13, 2018	BUY	$76.01 - $99.03 $223,545 - $291,247	2,941 New	2,941 $277,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Atria Investments LLC with notifications on news.